Prasinezumab clinical trials
Also written PRX002.
How each study uses prasinezumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the prasinezumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2017 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Hoffmann-La Roche (3) · Prothena Biosciences Limited (2) · University Hospital Tuebingen (1)
Studies
Open first, then newest update. How each study uses prasinezumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRecruitingPhase 3Hoffmann-La RocheNCT07174310Written as Prasinezumab
- Prevent Cognitive Decline in GBA-associated Parkinson's DiseaseRecruitingPhase 2University Hospital TuebingenNCT07055087Written as Prasinezumab
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseaseActive, not recruitingPhase 2Hoffmann-La RocheNCT03100149Written as RO7046015
- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseaseActive, not recruitingPhase 2Hoffmann-La RocheNCT04777331Written as Prasinezumab
- Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's DiseaseCompletedPhase 1Prothena Biosciences LimitedNCT02157714Written as PRX002
- Single Ascending Dose Study of PRX002 in Healthy SubjectsCompletedPhase 1Prothena Biosciences LimitedNCT02095171Written as PRX002
Codes
What other systems call prasinezumab · ClinicalTrials.gg INT017535
- UNII (FDA) P3Z0Z3P1ZIPRASINEZUMABOne source FDA
- NCI Thesaurus C174831PrasinezumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P3Z0Z3P1ZI | PRASINEZUMAB | One source FDA |
| NCI Thesaurus | C174831 | Prasinezumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.